Best Sliver Companies To Invest In Right Now

Automakers have been targeting the Asian market quite aggressively, and India seems to be among one of the most lucrative opportunities in the continent. Although India might not be able to match the growth witnessed in the automobile market in China, it is expected that 9.3 million units will be sold in the country by 2020. So, global automobile majors such as Ford (F) and many more are now targeting the Indian market.

Ford is currently targeting small passenger cars and mid-segment cars as it sees maximum potential in these areas. This is not surprising, considering passenger vehicle production in India is expected to reach 10 million units by 2020 to 2021. This segment of the Indian auto industry is expected to grow at a CAGR of 13% during the period 2012 to 2021, and automakers are targeting this.

The Indian Opportunity

The following points further suggest why leading automobile players such as Ford are keen on the Indian market:

India is projected to become the fourth-largest car market by 2015, overtaking the likes of the UK, Germany and France. India and China are expected to become important markets in the global automotive scene in the future. India is anticipated to become a part of the biggest automotive markets in the next two decades. Booz & Co. predicts that automobile sales in India may exceed the U.S. market in two decades.

Ford�� Moves

Hot Managed Healthcare Stocks To Invest In Right Now: Google Inc (GOOGL)

Google Inc. (Google), incorporated on October 22, 2002, is a global technology company. The Company�� business is primarily focused around key areas, such as search, advertising, operating systems and platforms, enterprise and hardware products. The Company generates revenue primarily by delivering online advertising. The Company also generates revenues from Motorola by selling hardware products. The Company provides its products and services in more than 100 languages and in more than 50 countries, regions, and territories. Effective September 16, 2013, Google Inc acquired Bump Technologies Inc. Effective October 22, 2013, Google Inc acquired FlexyCore, a developer of software. Effective December 6, 2013, Google Inc acquired the entire share capital of SCHAFT Inc. Effective December 14, 2013, Google Inc acquired Boston Dynamics Inc. Effective January 15, 2014, Google Inc acquired Impermium Corp, a developer of SaaS application software. Effective February 7, 2014, Google Inc acquired the remaining 88% interest in Nest Labs Inc. Effective February 21, 2014, Google Inc acquired Spider.io, a provider of online fraud detection services. Effective March 12, 2014, Google Inc acquired Green Throttle Games.

Search

The Company integrates features into its search service and offers specialized search services to help users tailor their search. The Company also offers product listing advertisements (ads), which include product information, such as product image, price, and merchant information, without requiring additional keywords or ad text. In January 2012, it launched Search plus Your World. During the year ended December 31, 2012, it also introduced Google Now and Google�� Knowledge Graph. Google Now is a search feature that gets the right information at just the right time. It tells the day�� weather before start of a day, how much traffic to expect before you leave for work or school, when the next train will arrive as you��e standing on the platform, or favorite team�! � score while they��e playing - all automatically with cards appearing throughout the day at the moment you need them. Google�� Knowledge Graph, enables the user to search for things, people or places that Google knows about-landmarks, celebrities, cities, sports teams, buildings, geographical features, movies, works of arts and more-and enhances Google Search in three ways: find the right thing, get the summary, and go deeper and broader.

Advertising

The Company�� AdWords is a primary auction-based advertising program, which delivers ads to search queries or Web content. With AdWords, advertisers create text-based ads that then appear beside related search results or Web content on its Websites and on thousands of partner Websites in its Google Network, which is the network of third parties that use its advertising programs to deliver relevant ads with search results and content. The Company also offers AdWords on a cost-per-impression basis that enables advertisers to pay the Company based on the number of times their ads appear on its Websites and the Company�� Google Network Members��Websites as specified by the advertiser. Its AdSense program enables Websites that are part of the Google Network to deliver ads from its AdWords advertisers that are relevant to the search results or content on Websites. In June 2012, the Company integrated its AdMob technology directly into its AdWords system, which enables advertisers to run campaigns across the more than 300,000 mobile applications running ads by AdMob - all from within the AdWords interface.

The Company�� Display advertising consists of videos, text, images, and other interactive ads that run across the Web on computers and mobile devices, including smart phones and handheld computers, such as net books and tablets. The Google Display Network provides advertisers services related to the delivery of display advertising across publishers participating in its AdSense program, publishers participat! ing in th! e DoubleClick Ad Exchange, and Google-owned sites, such as YouTube and Google Finance. Through its DoubleClick advertising technology, it provides to publishers, agencies, and advertisers the ad serving technology, which is the infrastructure that enables billions of ads to be served each day across the Web. Its DoubleClick Ad Exchange creates a real-time auction marketplace for the trading of display ad space. In addition, YouTube provides a range of video, interactive, and other ad formats for advertisers to reach their intended audience. YouTube�� video advertising solutions give advertisers a way to promote their content to the YouTube community, as well as to associate with content being watched by their target audience. YouTube also offers analytic tools to help advertisers understand their audience and derive general business intelligence.

The Company is focused on developing easy-to-use ad products to help advertisers extend their reach, help create revenue opportunities for its publisher partners, and deliver relevant and useful ads to users on the go. Google Mobile extends its products and services by providing mobile-specific features to mobile device users. The Company�� mobile-specific search technologies include search by voice, search by sight, and search by location. Google Mobile also optimizes a number of Google�� applications for mobile devices in both browser and downloadable form. In addition, the Company offers advertisers the ability to run search ad campaigns on mobile devices with mobile-specific ad formats, such as click-to-call ads in which advertisers can include a phone number within ad text. AdMob also offers effective ad units and solutions for application developers and advertisers. The Company provides users with relevant local information. The Company has organized information around more than 80 million places globally from various sources across the Web. Users can find addresses, phone numbers, hours of operation, directions and more for millions of! local qu! eries like shops, restaurants, parks and landmarks right on Google.com, on Google Maps and on Google Maps for mobile. Its products and services also help local business owners manage their online presence and connect with potential customers.

Operating Systems and Platforms

The Company�� Android is a free and open source mobile software platform that any developer can use to create applications for mobile devices and any handset manufacturer can install on a device. Google Chrome OS is an open source operating system with the Google Chrome Web browser as its foundation. Both the Google Chrome OS and the Google Chrome browser are built around the core tenets of speed, simplicity, and security. The Chrome browser runs on Windows, Mac, and Linux computers. Google+ is a new way to share online just like users do in the real world, sharing different things with different people. Google Play is a cloud-based, digital entertainment destination with more than 700,000 applications (apps) and games plus music, movies and books that its users can find, enjoy and share on the Web and on their Android phone or tablet. Google Drive is a place where users can create, share, collaborate, and keep all of their stuff. Google Docs is built right into Google Drive so users can work with others in real time on documents, spreadsheets and presentations and users��files go everywhere they do. Google Wallet is a virtual wallet that securely stores credit and debit cards, offers, and rewards cards. Users can tap their phone to pay in-store using Google Wallet anywhere contactless payments are accepted - at over 200,000 merchants across the United States. Google TV is a platform that gives consumers the power to experience television and the Internet on a single screen, with the ability to search and find the content they want to watch. The Google TV platform is based on the Android operating system and runs the Google Chrome browser.

Enterprise

The Company�� enterprise! products! provide Google technology for business settings. Through Google Apps, which includes Gmail, Google Docs, Google Calendar, and Google Sites, among other features, it provides hosted, Web-based applications that people can use on any device with a browser and an Internet connection. In addition, the Company provides its search technology for use within enterprises through the Google Search Appliance (real-time search of business applications, intranet applications, and public websites), on their public-facing sites with Google Site Search (custom search engine), and Google Commerce Search (for online retail enterprises). The Company also provide versions of its Google Maps Application Programming Interface (API) for businesses (including interactive Google Maps for public and internal Websites), as well as Google Earth Enterprise (a behind-the-company-firewall software solution for imagery and data visualization). Its enterprise solutions have been adopted by a variety of businesses, governments, schools, and non-profit organizations.

Motorola

The Company�� Motorola business consists of two segments: Mobile segment and Home segment. The Mobile segment is focused on mobile wireless devices and related products and services. The Home segment is focused on technologies and devices that provide video entertainment services to consumers by enabling subscribers to access a variety of interactive digital television services.

The Company competes with Facebook, Inc., Twitter Inc., Yahoo! Inc., Microsoft Corporation, eBay Inc., and Amazon.com, Inc.

Advisors' Opinion:

• [By Anna Prior]

  Google Inc.(GOOGL) posted a 3.2% increase in first-quarter net income amid a continuing decline in how much advertisers pay per click, as users shift to smartphones and tablets. Shares slipped 1.8% to $546.81 premarket.

Best Sliver Companies To Invest In Right Now: Bendigo and Adelaide Bank Ltd (BXRBF)

Bendigo and Adelaide Bank Limited (the Bank) is engaged in the range of banking and other financial services, including retail banking, mortgage distribution through third-parties, business lending, margin lending, business banking and commercial finance, invoice discounting, funds management, treasury and foreign exchange services (including trade finance), superannuation, financial advisory and trustee services. In retail banking it derives income from the provision of first mortgage finance less interest paid to depositors; and fee income from the provision of banking services delivered through the Company-owned branch network and the interest and fee income from the Community Bank branch network. In third party banking it derives income and fees from the manufacture and processing of residential home loans. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australia stocks enjoyed early Monday gains after an advance for commodities and U.S. stocks since the last session, with a relatively good reception for earnings. The S&P/ASX 200 (AU:XJO) improved by 0.4% to 5,376.30, with miners tracking gains in gold and copper. Rio Tinto Ltd. (AU:RIO) (RIO) added 1.3%, and Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) traded 1.1% higher, while gold miners Newcrest Mining Ltd. (AU:NCM) (NCMGF) and Kingsgate Consolidated Ltd. (AU:KCN) (KSKGF) rallied 2.2% and 4.7%, respectively. Banks rose after Wall Street shares climbed on Friday, with National Australia Bank Ltd. (AU:NAB) (NAUBF) up 1% and Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) adding 0.9%, though Commonwealth Bank of Australia (AU:CBA) (CBAUF) dropped 2.4% as it traded without rights to its latest dividend. Coal transport firm Aurizon Holdings Ltd. (AU:AZJ) (QRNNF) tacked on 2.1% as its fiscal first-half underlying profit increased 18%, though net profit f

Best Sliver Companies To Invest In Right Now: Cheniere Energy Partners LP (CQP)

Citigroup Funding Inc. offers debt instruments that include commercial papers, medium-term notes and structured equity-linked and credit-linked notes. Citigroup Funding, Inc. is based in United States. Citigroup Funding Inc. operates as a subsidiary of Citigroup, Inc.

Advisors' Opinion:

• [By Robert Rapier]

  Although it is the first of the first movers in this space, I think Cheniere Energy (NYSE: LNG) is fairly deep into speculative territory at this point. In 2012 Cheniere became the first to obtain approval from the Federal Energy Regulatory Commission (FERC) to export LNG to countries that lack a Free Trade Agreement (FTA) with the US. The non-FTA designation is important, because it covers many of the most lucrative LNG markets. Cheniere is the only company to have received the required approvals from both FERC and the US Department of Energy (DOE).  

  In 2007 Cheniere created the Cheniere Energy Partners (NYSE: CQP) master limited partnership to own assets such as its Sabine Pass LNG export terminal under construction on the Louisiana/Texas border, as well as another LNG terminal in Corpus Christi. Cheniere has signed up a number of customers in Asia and in Europe.  
  

  But the stock is surfing huge expectations that are already factored into the share price. While I believe there is money to be made in exporting natural gas, natural gas producers are lower-risk plays, followed by LNG tanker companies and gas infrastructure builders. LNG export backers are more aggressive and riskier options.

• [By Eric Volkman]

  Cheniere Energy (NYSEMKT: LNG  ) and closely related Cheniere Energy Partners (NYSEMKT: CQP  ) have released their Q1 results, and the news is sure to disappoint investors. For the former, its quarterly revenue was just under $66 million, down from the $70 million the company posted in the same period the previous year. Attributable net loss widened considerably, to $117 million ($0.54 per diluted share) from Q1 2012's shortfall of $56 million ($0.43).

Best Sliver Companies To Invest In Right Now: Manhattan Associates Inc.(MANH)

Manhattan Associates, Inc. develops, sells, deploys, services, and maintains supply chain software solutions for the planning and execution of supply chain activities. It offers Manhattan SCOPE and Manhattan SCALE, which are platform-based supply chain software solutions. The company?s Manhattan SCOPE is a portfolio of supply chain solution suites that include event and schedule tracking; alerts and notifications; inventory, order, and shipment visibility; cost monitoring and tracking; leading-edge analytics; and reporting with graphical depictions of critical supply chain performance metrics. Manhattan SCOPE also includes X-Suite solutions comprising flow management and extended enterprise management. The company?s Manhattan SCALE is a portfolio of logistics execution solutions that offer trading partner management, yard management, optimization, warehouse management, and transportation execution services. Manhattan Associates, Inc. also offers professional services, in cluding planning and implementation services; and customer support, software enhancement, and training services. In addition, it sells computer hardware, radio frequency terminal networks, radio frequency identification chip readers, bar code printers and scanners, and other peripherals. The company serves retailers, distributors, wholesalers, manufacturers, grocery stores, life sciences companies, government, and other organizations. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Manhattan Associates, Inc. was founded in 1990 and is headquartered in Atlanta, Georgia.

Advisors' Opinion:

• [By Seth Jayson]

  Manhattan Associates (Nasdaq: MANH  ) reported earnings on April 23. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Manhattan Associates met expectations on revenues and beat expectations on earnings per share.

Best Sliver Companies To Invest In Right Now: United Therapeutics Corporation(UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and internationally. It offers Remodulin, Tyvaso, and Adcirca for the treatment of pulmonary arterial hypertension (PAH). The company also develops Oral Treprostinil (UT-15C), a new drug application filed with the United States Food and Drug Administration for the treatment of PAH. Its development products under Phase III clinical trials include Oral Treprostinil (UT-15C) Combination Therapy for PAH; Ch14.18 monoclonal antibody (MAb) targeting Neuroblastoma; and Remodulin for the treatment of PAH in the United States, the United Kingdom, France, Germany, Italy, and Japan. The company?s development products under Phase I clinical trials comprise Beraprost-MR for PAH in North America, Europe, Mexico, South America, Egypt, India, South Africa, and Australia; 8H9 MAb targ eting Metastatic brain cancer; and IW001 for the treatment of Idiopathic pulmonary fibrosis and primary graft dysfunction. Its pre-clinical stage products consist of Glycobiology Antiviral Agents for viral infectious diseases; PLacental eXpanded cells targeting PAH; and pulmonary tissue replacement and remodeling products for the treatment of end-stage lung disease. The company serves pharmaceutical wholesalers through specialty pharmaceutical distributors and other distributors. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Advisors' Opinion:

• [By Life Sciences Report]

  AF: On the large-cap side, we like United Therapeutics Corp. (UTHR) and Vertex Pharmaceuticals Inc. (VRTX). United Therapeutics, in particular, has fallen out of favor somewhat, especially relative to the level of investor interest in the name 5-6 years back. Institutional holders have shifted from a largely biotech specialist group to a mix of value and generalist stocks. The upshot is that incremental buying on the part of healthcare specialists, as they re-engage with the name, ought to have a very positive impact on United Therapeutics' share price.

• [By Ben Levisohn]

  Look up in the sky! It’s a bird! It’s a plane! It’s Santa Claus! No. It’s United Therapeutics (UTHR).

  Reuters

  Shares of the United Therapeutics have surged 23% to $107.65, on what’s looking to be a pretty decent day for biotech stocks. The iShares Nasdaq Biotechnology Index ETF (IBB) has gained 0.9% to $225.75, as Gilead Sciences (GILD) has risen 0.7% to $75.16 and Celgene (CELG) has ticked up 0.4% to $168.09.

• [By Ben Levisohn]

  United Therapeutics (UTHR) has zoomed to a 52-week high after a patent court gave it a partial victory in a lawsuit involving one of its drugs. ISI Group’s Mark Schoenebaum explains:

  Agence France-Presse/Getty Images

  The court ruling for the�United Therapeutics / Sandoz case was just posted. The judge ruled in favor of�United Therapeutics on the 2017 patent and in favor of Sandoz on the 2029 patent (United Therapeutics patent valid but Sandoz does not infringe) giving�United Therapeutics likely an additional 3 years protection on Remodulin.

  Investors were skeptical of a win on the 2017 patent (and gave very little credit to the 2029 patent given it was only on the diluent and Sandoz could have possibly just gotten a carve-out on the label). So this is close to a best case scenario in our view as the big overhang on�United Therapeutics appears to now be behind them and investors can consider owning�United Therapeutics for the potential for better than expected oral Orenitram sales.

  An additional 3 years of Remodulin protection adds ~$10 to our DCF.

  Leerink’s Joseph Schwartz and Paul Matteis doesn’t think the news is as good as the market thinks it is:

  While the order is likely to lead to a modest raise of near term consensus estimates, we believe that the decision re-affirms our long-term cautious view on�United Therapeutics shares given the 1) near certainty now that Remodulin will go generic in 2H17 and 2) greater need for�United Therapeutics to create value through creatively deploying its free cash flow, which in recent history has mostly been used to fund operations and buy back stock. Thus, while the ruling today likely solifidies United Therapeutics’ 2015-2016 earnings potential, based on our sensitivity analysis we believe that the near certain presence of a generic in 2017 implies significant downside to the NPV of the remodulin franchise, contrary to the positive stock reaction to the

Best Sliver Companies To Invest In Right Now: Shire PLC (SHPG)

Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.

VANSE/ VENVANSE

VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.

ADDERALL XR

ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.

INTUNIV

INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.

EQUASYM

Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.

LIALDA/MEZAVANT

LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.

PENTASA

PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.

RESOLOR

RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.

XAGRID

XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.

REPLAGAL

REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.

ELAPRASE

ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.

VPRIV

VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.

FIRAZYR

FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.

DERMAGRAFT

DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.

The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.

Advisors' Opinion:

• [By Jayson Derrick]

  Analysts at CRT Capital maintained a Buy rating on Shire (NASDAQ: SHPG) with a price target raised to $233 from a previous $225. Shares gained 0.71 percent, closing at $195.87.

• [By MONEYMORNING.COM]

  Recently these deals have been focused on the pharmaceutical and healthcare industries, and stocks in those industries took a dive after the Treasury released its new regulations on Monday. British pharmaceutical giant AstraZeneca Plc. (NYSE ADR: AZN), which had been the target of a failed inversion bid by U.S. drug maker Pfizer Inc. (NYSE: PFE), dropped 3.6%. AbbVie Inc. (NYSE: ABBV), which is involved in a $54 billion deal to buy Irish pharmaceutical giant Shire Plc. (Nasdaq ADR: SHPG), was down 1.9%. Covidien Plc. (NYSE: COV), an Irish company being bought by American medical device maker Medtronic Inc. (NYSE: MDT) was down 3%.

• [By Eddie Staley]

  AbbVie (NYSE: ABBV) lifted its offer to buy Shire plc (NASDAQ: SHPG) to 30.1 billion pounds ($51.3 billion).

  The latest offer for Shire is approximately an 11 percent increase from the previous bid. The new offer stands at £22.44 cash and 0.8568 AbbVie shares for each Shire share, or £51.15 total.

• [By Matt Egan]

  These transactions occur when a U.S. corporation moves its legal headquarters overseas after buying a foreign company that is based in a low-tax country. Medtronic's (MDT) takeover of Ireland's Covidien (COV) and drug maker AbbVie's (ABBV) plan to move to the U.K. by buying Shire (SHPG) are examples.

Best Sliver Companies To Invest In Right Now: Cenovus Energy Inc (CVE)

Cenovus Energy, Inc. (Cenovus), incorporated on January 1, 2011, is a Canadian integrated oil company. The Company�� operations include oil sands projects in northern Alberta, which use specialized methods to drill and pump the oil to the surface. It also has natural gas and oil production in Alberta and Saskatchewan. It operates in four segments: oil sands, conventional, refining and marketing, and corporate and eliminations. The Company has 50% ownership with Phillips 66 in two United States refineries, which includes Wood River (Illinois) and Borger (Texas) refineries. It has two producing steam-assisted gravity drainage (SAGD) projects in the oil sands-Foster Creek and Christina Lake, as well as several emerging projects which are in various stages of development. Foster Creek and Christina Lake are 50%-owned by ConocoPhillips. It also produces heavy oil from the mobile Wabiskaw formation at its 100%-owned Pelican Lake operation in the Greater Pelican Region, about 300 kilometers north of Edmonton.

Its reserves and production are located in Canada, primarily within the provinces of Alberta and Saskatchewan. As of December 31, 2012, it had a land base of approximately seven million net acres and Company Interest Before Royalties proved reserves of approximately 1,717 million barrels of bitumen, 184 million barrels of heavy crude oil, 115 million barrels of light and medium crude oil and NGLs and 955 billion cubic feet of natural gas. It also had Company Interest Before Royalties probable reserves of approximately 676 million barrels of bitumen, 105 million barrels of heavy crude oil, 56 million barrels of light and medium crude oil and natural gas liquefied (NGLs) and 338 billion cubic feet of natural gas as of December 31, 2012.

Oil Sands

The Oil sands segment includes the development and production of Cenovus�� bitumen assets at Foster Creek, Christina Lake and Narrows Lake, as well as heavy oil assets at Pelican Lake. This segment also includes the Atha! basca natural gas assets and projects in the early stages of development, such as Grand Rapids and Telephone Lake. Certain of the Company�� operated oil sands properties, notably Foster Creek, Christina Lake and Narrows Lake, are jointly owned with ConocoPhillips. As of December 31, 2012, it had bitumen rights of approximately 1,469,000 gross acres (1,097,000 net acres) within the Athabasca and Cold Lake areas, as well as the exclusive rights to lease an additional 478,000 net acres areas on the Cold Lake Air Weapons Range on its behalf and/or its assignee�� behalf.

As of December 31, 2012, there were 56 wells producing. It operates an 80 megawatt natural gas-fired cogeneration facility in conjunction with the SAGD operation at Foster Creek. The steam and power generated by the facility is presently being used within the SAGD operation and the excess power generated is being sold into the Alberta Power Pool. It has 50% interest in Christina Lake, an oil sands property in northeast Alberta that uses SAGD technology and produces from the McMurray formation. During 2011, the Company drilled three wells at Christina Lake using its Wedge WellTM technology. As of December 31, 2012, there were six producing wells.

The Company holds 50% interest in Narrows Lake, an oil sands property within the Christina Lake Region in northeast Alberta. The project includes gross production capacity of 130,000 barrels per day (bbls/d) of bitumen to be developed in up to three phases, with the first phase expected to have production capacity of approximately 45,000 barrels per day of bitumen. Using a pattern, horizontal well polymer flood, it produces heavy crude oil from the Cretaceous Wabiskaw formation at its Pelican Lake property, which is located within the Greater Pelican Region in northeast Alberta. During 2012, it drilled 76 heavy oil wells. The Company holds a 38% non-operated interest in 110 kilometers, 20-inch diameter crude oil pipeline, which connects the Pelican Lake area to a pipelin! e that tr! ansports crude oil from northern Alberta to crude oil markets.

The Company�� new resource play assets include oil sands properties. Its Grand Rapids property is located in the Greater Pelican Region in northeast Alberta, where deposits of bitumen have been identified in the Cretaceous Grand Rapids formation. Its Telephone Lake property is located in the Borealis Region in northeast Alberta. The Steepbank and East McMurray properties are also located in the Borealis Region, southwest of Telephone Lake. It produces natural gas from the Cold Lake Air Weapons Range and several surrounding landholdings located in northeast Alberta and hold surface access and natural gas rights for exploration, development and transportation from areas. The majority of its natural gas production in the area is processed through wholly owned and operated compression facilities.

Conventional

Conventional segment includes the development and production of conventional crude oil, NGLs and natural gas in Alberta and Saskatchewan. It includes the carbon dioxide enhanced oil recovery project at Weyburn and emerging tight oil opportunities. As of December 31, 2012, it had an established land position of approximately 4.9 million gross acres, of which approximately 3.2 million gross acres are developed. The mineral rights on approximately 59% of its net landholdings are owned in fee title by Cenovus. It leases Crown lands in some areas in Alberta, mainly in the Early Cretaceous geological formations, primarily in the Suffield and Wainwright areas.

The Company holds interests in multiple zones in the Suffield, Brooks North, Langevin, Drumheller, and Wainwright areas in southern Alberta with a mix of medium and heavy crude oil production. Development in these areas focuses on infill drilling, optimization of existing wells and other specialized oil recovery methods. It operates water handling facilities to manage oil production. In the unitized portion of the Weyburn crude oil field ! in southe! ast Saskatchewan, it has 62% working interest. The Weyburn unit produces light and medium sour crude oil from the Mississippian Midale formation and covers 78 sections of land. As of December 31, 2012, approximately 90% of the approved CO2 flood pattern development at the Weyburn unit was completed. It holds interests in multiple zones in the Suffield, Brooks North, Langevin and Drumheller areas in southern Alberta.

Refining and Marketing

Refining and marketing segment is focused on the refining of crude oil products into petroleum and chemical products at two refineries located in the United States. The refineries are jointly owned with and operated by Phillips 66. This segment also markets Cenovus�� crude oil and natural gas, as well as third-party purchases and sales of product that provide operational flexibility for transportation commitments, product type, delivery points and customer diversification.

Through WRB Refining LP (WRB), the Company has 50% ownership interest in both the Wood River and Borger Refineries located in Roxana, Illinois and Borger, Texas respectively. ConocoPhillips is the operator and manager of WRB. As of December 31, 2012, the Wood River refinery had a processing capacity of approximately 306,000 barrels per day of crude oil, including approximately 110,000 barrels per day of heavy crude oil. It processes light low-sulphur and heavy high-sulphur crude oil that it receives from North American crude oil pipelines to produce gasoline, diesel and jet fuel, petrochemical feedstocks and asphalt. As December 31, 2012, the Borger Refinery had a processing capacity of approximately 146,000 barrels per day of crude oil, including approximately 35,000 barrels per day of heavy crude oil, and approximately 45,000 barrels per day of NGLs. It processes crude oil and NGLs that it receives from North American pipeline systems to produce gasoline, diesel and jet fuel along with NGLs and solvents.

The Company's Marketing group is focused ! on enhanc! ing the netback price of its production. It manages the transportation and marketing of crude oil for its upstream operations. It also manages the marketing of its natural gas, which is primarily sold to industrials, other producers and energy marketing companies.

Corporate and Eliminations

The segment includes inter-segment eliminations that relate to transactions that have been recorded at transfer prices based on current market prices, as well as unrealized intersegment profits in inventory. The Corporate and Eliminations segment also includes Cenovus costs for general and administrative and financing activities.

Advisors' Opinion:

• [By gurujx]

  Cenovus Energy, Inc. (CVE) Reached the 3-year Low of $28.17

  The prices of Cenovus Energy, Inc. (CVE) shares have declined to close to the 3-year low of $28.17, which is 33.3% off the 3-year high of $40.73.

• [By Robert Rapier]

  Whether KXL is approved is unlikely to have a big impact on any particular company. TransCanada would probably see the most significant share price movement, but the project isn�� a make-or-break for the company. Oil sands producers like Cenovus Energy (NYSE: CVE, TSE: CVE) have signed up to ship on KXL, and could see some share price movement as well. KXL would probably be the low-cost shipping option for Cenovus and other oil sands producers, but during my visit to Fort McMurray in November Cenovus emphasized that whether KXL is approved or not, the outcome would have no effect on its growth plans given the ready availability of alternatives.

• [By Holly LaFon]

  We also added Cenovus (CVE) to the Worldwide High Dividend portfolio during the quarter. This Canadian oilsands operator has a strong production growth profile with low cost in situ oilsands reserves. At purchase, Cenovus was trading at a substantial discount from our estimate of intrinsic value and was paying a dividend yield of 3.2%.